Clinical Trials
All Clinical Trials - Page 64 of 74
A complete, crawlable index of every tracked clinical trial of peptide compounds. Use the search browser at /trials for filtering, or page through the full list here.
- NCT00948168Phase 4Completed
Effect of Exenatide on Glucose Homeostasis Determinants in Type 2 Diabetes
Exenatide
- NCT00717457Phase 3Completed
A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.
Exenatide
- NCT00715624Phase 3Completed
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin
Lixisenatide
- NCT00713830Phase 3Completed
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea
Lixisenatide
- NCT01153425Phase 4Completed
µMRI of Therapeutic Intervention in Postmenopausal Osteoporosis
Teriparatide
- NCT00747500N/ACompleted
Non Interventional Post Marketing Programme in Acromegaly
Lanreotide
- NCT00696657Phase 2Completed
A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide
Semaglutide
- NCT00651326Phase 3Terminated
Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer
Gonadorelin
- NCT00635817Phase 3Completed
A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty
Gonadorelin
- NCT00658697Phase 2Completed
Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer
Gonadorelin
- NCT00700817Phase 3Completed
The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus
Liraglutide
- NCT00855439N/ACompleted
Evaluation of Exenatide in Patients With Diabetic Neuropathy
Exenatide
- NCT00707031Phase 3Completed
GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin
Exenatide
- NCT00712673Phase 3Completed
GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin
Lixisenatide
- NCT00696644N/ACompleted
A Study for Teriparatide in Severe Osteoporosis
Teriparatide
- NCT01155245N/AActive Not Recruiting
Teriparatide (PTH) and Bone Strength in Postmenopausal Women
Teriparatide
- NCT00652379N/ACompleted
Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients
Octreotide
- NCT00681187Phase 4Completed
Somatuline Autogel Preference and Health Economy Study
Lanreotide
- NCT00658021Phase 3Completed
Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes
Exenatide
- NCT02012556Phase 1Completed
Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive Patients
Tesamorelin
- NCT00711620N/ACompleted
Efficacy of Thymosin alpha1 for Severe Sepsis
Thymosin-Alpha-1
- NCT00630799Phase 3Terminated
Efficacy and Safety Study of a New Leuprolide Acetate 17 mg Depot to Treat Prostate Cancer Patients
Gonadorelin
- NCT00688701Phase 3Completed
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy
Lixisenatide
- NCT00623974Phase 2Terminated
Teriparatide (Forteo) in the Treatment of Patients With Postoperative Hypocalcemia
Teriparatide
- NCT00686348N/ACompleted
Somatuline® Depot (Lanreotide) for Acromegaly Post-Marketing Observational Study
Lanreotide
- NCT00690898Phase 3Completed
Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma
Lanreotide
- NCT00517491Phase 2Withdrawn
Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)
Lanreotide
- NCT00743769Phase 1Withdrawn
A Phase 1 Safety Study of the Intravenous Administration of Thymosin Beta in Healthy Volunteers
TB-500
- NCT00672074Phase 2Completed
Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus
Ipamorelin
- NCT00630825Phase 2Completed
A Study of Dose Titration of LY2189265 in Overweight Participants With Type 2 Diabetes Mellitus
Dulaglutide
- NCT01154933Phase 2Completed
Exeantide in Type 2 Diabetes on Insulin
Exenatide
- NCT00641056Phase 3Completed
Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)
Exenatide
- NCT00806520N/ACompleted
Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control
Exenatide
- NCT01076842Phase 4Completed
Efficacy Evaluation of Different Medication Combination in Type 2 Diabetes Treatment
Exenatide
- NCT00672399Phase 1Completed
Electrophysiological Effects of a Single 10 μg Dose of Exenatide on the 12-Lead Electrocardiogram QT Interval in Healthy Subjects
Exenatide
- NCT00673387Phase 2Completed
Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects
Pramlintide
- NCT00535860Phase 2Completed
Efficacy & Safety of ViaDerm-hPTH(1-34) Compared to Forteo SC in Postmenopausal Women With Osteoporosis
Teriparatide
- NCT00582426Phase 3Completed
Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea
Octreotide
- NCT00690430Phase 3Completed
Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease
Octreotide
- NCT01923649Phase 2Completed
SOMATULINE Autogel 90 mg IN DUMPING SYNDROME
Lanreotide
- NCT00771888Phase 2/Phase 3Unknown
Open-Label Extension of LOCKCYST Trial
Lanreotide
- NCT00624481Phase 2Withdrawn
Study to Evaluate Effect of Intranasal Teriparatide on Bone Mineral Density in Postmenopausal Women With Low BMD
Teriparatide
- NCT06080204N/ACompleted
Real-world Study on Adjuvant Octreotide Therapy in pNETs
Octreotide
- NCT00630695Phase 3Completed
Prevention of Lymphorrhea by Lanreotide in Axillary Dissection for Breast Cancer
Lanreotide
- NCT00600886Phase 3Completed
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
Octreotide
- NCT01813097N/ACompleted
Combination Iodine 125 Seed Implants and LHRH Agonists for Locally Advanced (Stage T3) Prostate Cancer
Gonadorelin
- NCT00626431Phase 3Completed
A Study of Leuprolide to Treat Prostate Cancer
Gonadorelin
- NCT00567580Phase 3Unknown
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
Gonadorelin
- NCT00620282Phase 3Completed
The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus
Liraglutide
- NCT01021527Phase 1Completed
A Study to Assess the Effects of Exenatide on Insulin Secretion Rates Using a Graded Infusion of Intravenous Glucose (0000-099)(COMPLETED)
Exenatide